Five Prime Therapeutics Inc. (FPRX)
Symbol Info
Listed Symbol FPRX
Name Five Prime Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $49,868,000
Latest Fiscal EPS $-4.11
Price Info
21 Day Moving Average $4.1945
21 Day EMA $4.299490
50 Day Moving Average $5.0403
50 Day EMA $4.888020
200 Day EMA $8.124480
200 Day Moving Average 8.445880
52 Week High $14.45
52 Week Low $3.22
52 Week Change $-71.980300
Alpha -0.016453
Beta 2.5497
Standard Deviation 0.226878
R2 0.148949
Periods 60
Share Information
10 Day Average Volume 409,981
20 Day Average Volume 449,368
30 Day Average Volume 385,670
50 Day Average Volume 333,628
Outstanding Shares 36,781,385
Float Shares 35,567,213
Percent Float 96.70%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 286
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 3,071,999
Institute Holdings Percent 96.400000
Institute Sold Previous 3 Months 10,844,925
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 15
Insider Holdings Percent 3.30%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,214,172
Price Change
7 Day Price Change $-0.1499999
7 Day Percent Change -3.62%
21 Day Price Change $-0.2850001
21 Day Percent Change -6.67%
30 Day Price Change $-1.3500001
30 Day Percent Change -25.28%
Month To Date Price Change $0.1150
Month To Date Percent 2.97%
90 Day Price Change $-1.6
90 Day Percent Change -28.62%
Quarter To Date $0.115000
Quarter To Date Percent 2.97%
180 Day Price Change $-7.92
180 Day Percent Change -66.50%
200 Day Price Change $-9.33
200 Day Percent Change -70.05%
Year To Date $-5.31
Year To Date Percent -57.10%
Profile
Description Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.
Details
Issue Type CS
Market Cap $146,757,726
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 36,781,385
CEO William R. Ringo
Employees 210
Last Audit UE
Classification
CIK 0001175505
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 111 Oyster Point Boulevard
South San Francisco, CA 94080
Website http://www.fiveprime.com
Facisimile +1 415 365-5601
Telephone +1 415 365-5600
Email ir@fiveprime.com
Key Ratios
Profitability
EBIT Margin -874.9
EBITDA Margin -846.6
Pre-Tax Profit Margin -218.3
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $12,711,000
Revenue Per Share $0.3456
Revenue 3 Years $-38.61
Revenue 5 Years $-4.68
Valuation Measures
PE Ratio -
Enterprise Value $-20,171,134
Price To Sales 11.545726
Price To Free Cash -1.3
PE High Last 5 Years -
Price To Book 0.7
Price To Cash Flow 4.8
PE Low Last 5 Years -
Price To Tangible Book 0.7
Financial Strength
Total Debt To Equity 0.3
Int Coverage -
Current Ratio 6.9
Leverage Ratio 1.4
Quick Ratio 6.5
Long Term Debt To Capital 0.19
Assets
Receivables Turnover 0.9
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -45.17
Return On Equity -57.33
Return On Capital -50.06
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type
Your Recent History
NASDAQ
FPRX
Five Prime..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191022 14:03:28